A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus (Eluminate-1)
A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus (Eluminate-1)
The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron alone or in combination with dapagliflozin compared with placebo in adults with type 2 diabetes mellitus (T2DM) inadequately managed with lifestyle management alone or treated with other background glucose-lowering medication.
Inclusion Criteria:
Exclusion Criteria:
information.center@astrazeneca.com1-877-240-9479
CABA, C1120AAC, Argentina
Caba, C1128AAF, Argentina
Ciudad de Buenos Aires, C1094AAD, Argentina
Suining Shi, 629000, China
Amagasaki-shi, 660-8550, Japan
Chitose-shi, 066-0032, Japan
Koga-shi, 306-0232, Japan
Oyama-shi, 323-0022, Japan
Shinjuku-ku, 169-0072, Japan
Zentsuji-shi, 765-0071, Japan
Jongno-gu, 110-746, South Korea
Tainan County, 71044, Taiwan